Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer

British Journal of Surgery

Volumn 96, Issue 2, 2009, Pages 166-170

  Gil Rendo, A ^a   Martinez Regueira F ^a   Zornoza, G ^a   Garcia Velloso M J ^a   Beorlegui, C ^a   Rodriguez Spiteri, N ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PAGET NIPPLE DISEASE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 60049099374     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6459     Document Type: Article

References (17)

1. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39:4-8.
2. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998; 82: 2227-2234.
3. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005; 467: 1144-1150.
4. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26: 226-230.
5. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ et al. Evaluation of preoperative chemotherapy using PET with fluorine-18- fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37: 931-938.
6. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007; 73: 1151-1157.
7. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008; 38: 250-258.
8. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
9. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
10. Crowe JP Jr, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1: 132-140.
11. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol 2004; 130: 273-278.
12. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29: 1317-1323.
13. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
14. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008; 112: 995-1000.
15. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, van Dienst PJ et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20: 379-387.
16. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 3495-3502.
17. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Seenn HJ et al. First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17: 1772-1776.